A product of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY), BYETTA® (exenatide) injection has been approved by the USFDA as an add-on therapy to improve blood sugar control in people with type 2 diabetes who have not achieved adequate control on a thiazolidinedione (TZD).
According to Dr. Robert Ratner, Vice President for Scientific Affairs at the MedStar Research Institute in Washington, DC: 
Find more details from the press release at Amylin."Due to the progressive nature of type 2 diabetes, previous approaches to management frequently failed to achieve target levels of A1C, or resulted in subsequent failure over one to three years.
The combination of exenatide with metformin, sulfonylureas, or TZDs not only expands our options to achieve optimal glycemic control, but does so with accompanying weight loss."
Comment Preview